Navigation Links
Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
Date:10/7/2009

CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 17th Annual BioPartnering Europe conference in London, U.K. on Monday, October 12 at 10:15 a.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 11-13, 2009.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
2. Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America
3. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
4. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
5. Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
6. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
7. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
8. Bio-enabled, surface-mediated approach produces nanoparticle composites
9. avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
10. Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit
11. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 , ... ... model aircraft flying hobbyists, and the University Aviation Association (UAA), the unifying voice ... The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through a STEM-based ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product ... who suffers from hay fever, urticaria, asthma, atopic eczema or a food allergy. ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line HeLa, ... the first data on cross-contamination of human cell lines with HeLa cells were published. ... in cell culture labs and is associated with dramatic consequences for research. , ...
(Date:6/20/2017)... Lauderdale, Florida (PRWEB) , ... June 20, 2017 , ... ... commitment in men. While researching her latest book, Men Chase, Women Choose: The Neuroscience ... showed that love has a physiological effect on men. ”The logical next step, in ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):